Background-The burden of subclinical atherosclerosis in asymptomatic individuals is heritable and associated with elevated risk of developing clinical coronary heart disease. We sought to identify genetic variants in protein-coding regions associated with subclinical atherosclerosis and the risk of subsequent coronary heart disease. Methods and Results-We studied a total of 25 109 European ancestry and African ancestry participants with coronary artery calcification (CAC) measured by cardiac computed tomography and 52 869 participants with common carotid intima-media thickness measured by ultrasonography within the CHARGE Consortium (Cohorts for Heart and Aging Research in Genomic
C oronary heart disease (CHD) remains the leading cause of death and infirmity in developed countries. 1 Atherosclerosis is the underlying pathology of CHD. 2 The presence of atherosclerosis in individuals without clinical CHD, termed subclinical atherosclerosis, is associated with increased risk of developing clinical CHD independent of traditional risk factors prior to the onset of symptoms. [3] [4] [5] [6] Subclinical atherosclerosis is a heritable [7] [8] [9] clinical phenotype that can be ascertained noninvasively as coronary artery calcification (CAC) by cardiac computed tomography and common carotid intima-media thickness (CIMT) by carotid ultrasound. 10 
Clinical Perspective on p 520
Genome-wide association studies within the CHARGE Consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology) have discovered sites of common noncoding genetic variation associated with both CAC 11, 12 and CIMT 7,11 among those of European ancestry. Noncoding single nucleotide polymorphisms at the 9p21 and 6p24 regions, near the CDKN2A and PHACTR1 genes, respectively, are strongly associated with both CAC burden and myocardial infarction. 12 The 8q24 (ZHX2), 19q13 (APOC1), and 8q23 (PINX1) loci are strongly associated with CIMT. 7 Observed associations for subclinical atherosclerosis among individuals of European ancestry, however, have not been replicated in those of African ancestry. 13, 14 Furthermore, because the biological implications of noncoding variation are not as readily interpreted as with coding variation, the roles of such variants in human atherosclerosis remain unclear. 15 Protein-coding variation tends to be infrequently observed and is often inadequately catalogued on earlier genome-wide association study arrays. 16 Rare genomic variation is not well imputed, and exome sequencing to detect such uncommon variation across large populations remains a costly endeavor. Here, we leverage the Illumina HumanExome BeadChip array, enriched for protein-coding variation. 17 We investigated whether there is evidence for associations of protein-coding variation with 2 measures of subclinical atherosclerosis across individuals of European and African ancestry. And we further determine whether such DNA sequence variations may influence CHD risk.
Methods

Study Populations
The Illumina HumanExome Beadchip v1.0 or v1.1 (also known as the exome chip) was used to genotype participants across 19 cohorts of the CHARGE Consortium (Data Supplement). 18 Participants with a diagnosis of CHD at the time of CAC phenotyping were excluded from CAC analysis. Participants who underwent carotid endarterectomy prior to CIMT phenotyping were excluded from CIMT analysis. 25 109 participants had CAC measured, and 52 869 participants had CIMT measured. Each study received institutional review board approval, participants provided written informed consent, and respective governing ethics committees approved each study.
Measures
CAC Measurement
Cohorts used different computed tomography scanners to ascertain CAC scoring ( Table I in the Data Supplement) . CAC scorings by multidetector computed tomography and by electron beam computed tomography have been previously described to be highly concordant and are both recognized as valid tools to estimate CAC score. [19] [20] [21] Total CAC score was quantified by the sum of CAC area weighted by density within individual coronary arteries by the Agatston method, and the continuous score was used for analysis. 22 
CIMT Measurement
Common CIMT was derived by bilateral longitudinal common carotid artery analysis (imaging and measurement methods are described in the Table II in the Data Supplement). The mean of the maximum thickness for each common carotid artery was the analytic variable.
Statistical Analyses
According to prespecified analysis plans, association analyses and meta-analyses were performed using the seqMeta package (http:// cran.r-project.org/web/packages/seqMeta/index.html) in the R statistical software as has previously been performed for exome chip-based analyses. 23 To reduce skewness, CAC was natural log transformed after adding 1 and CIMT was natural log transformed. Each cohort performed an analysis for each genomic variant, with the trait of interest independently and separately for individuals of European and African ancestry to minimize population biases. Covariates in the models included age, sex, and principal components of ancestry derived using EIGENSTRAT. 24 For studies with related samples, the pairwise kinship matrix was computed and accounted for in the regression model. Score statistics and genotypic covariance matrices were computed for each cohort and used for additive single variant and gene-based analyses, respectively.
For our primary analyses, we tested the association of each genomic variant with CAC and with CIMT across all samples by Epidemiology). Participants were genotyped for 247 870 DNA sequence variants (231 539 in exons) across the genome. A meta-analysis of exome-wide association studies was performed across cohorts for CAC and carotid intima-media thickness. APOB p.Arg3527Gln was associated with 4-fold excess CAC (P=3×10 −10 ). The APOE ε2 allele (p.Arg176Cys) was associated with both 22.3% reduced CAC (P=1×10 −12 ) and 1.4% reduced carotid intima-media thickness (P=4×10 −14 ) in carriers compared with noncarriers. In secondary analyses conditioning on low-density lipoprotein cholesterol concentration, the ε2 protective association with CAC, although attenuated, remained strongly significant. Additionally, the presence of ε2 was associated with reduced risk for coronary heart disease (odds ratio 0.77; P=1×10 −11 ). Conclusions-Exome-wide association meta-analysis demonstrates that protein-coding variants in APOB and APOE associate with subclinical atherosclerosis. APOE ε2 represents the first significant association for multiple subclinical atherosclerosis traits across multiple ethnicities, as well as clinical coronary heart disease.
(Circ Cardiovasc Genet. 2016;9:511-520. DOI: 10.1161/CIRCGENETICS.116.001572.)
Key Words: carotid intima-media thickness ◼ coronary artery calcification ◼ exome ◼ genome-wide association study ◼ genomics meta-analysis that included all cohorts, irrespective of ancestry. We performed single-variant analyses on variants that had a minor allele count of at least 20 and gene-based analyses for genes with combined minor allele frequency (MAF) of nonsynonymous variants at least 0.2% to reduce the likelihood of false-positive results. We also performed 2 gene-based tests: (1) T1, where nonsynonymous variants with MAF <1% were collapsed into a gene-based statistic, and (2) sequence kernel association test with MAF <5% for nonsynonymous variants to better account for collapsed variants with bidirectional phenotypic consequences. Regional association plots were generated using LocusZoom. 25 For our secondary analyses, we tested the association of each genomic variant with CAC and CIMT by meta-analysis separately among cohorts of European and African ancestry. Given the 238 065 variants on the array that passed quality control, the Bonferroni-adjusted level of significance for single variant tests was 0.05/238 065=2.10×10 −7 . Given the 17 574 genes with nonsynonymous variants on the array, the Bonferroni-adjusted level of significance for gene-based tests was 0.05/17 574=2.85×10 −6 . For CAC, we had >90% power to detect a variant (MAF <1%) with effect size 0.31 standard deviations or a gene (combined MAF <1%) with effect size 0.28 standard deviations at a sample size of 25 000. For CIMT, we had >90% power to detect a variant (MAF <1%) with effect size 0.21 standard deviations or a gene (combined MAF <1%) with effect size 0.20 standard deviations with a sample size of 52 000. Power calculations were performed using the Genetic Power Calculator. 26 Methods for the secondary analyses are presented in the Data Supplement.
Results
Study Participants
Nineteen cohorts participated in the meta-analyses of these 2 subclinical atherosclerotic traits, and the clinical characteristics are summarized in Tables I and II in the Data Supplement. A total of 25 109 participants were genotyped with the array and had CAC assessed; of these participants, 19 980 were of European ancestry and 5129 were of African ancestry. 52 869 participants were genotyped and had CIMT assessed; 44 963 were of European ancestry and 7906 were of African ancestry. 222 701 (93.5%) of the 238 065 variants were polymorphic in the CAC meta-analysis; of polymorphic variants, 193 373 (97.1%) were annotated as nonsynonymous or splicesite variants. Similarly, 227 344 (95.5%) of array variants were polymorphic in the CIMT meta-analysis, and of these, 217 235 (95.6%) were nonsynonymous or splice-site variants. Figure 1 plots the meta-analysis CAC association P value by genomic locus for each variant. The top loci with lead variants associated with CAC among all participants are listed in Table 1 . No systematic association inflation was observed across the set of statistical tests performed ( Figure I in the Data Supplement).
CAC Association
We identified previously described common noncoding variant associations at the 9p21 and 6p24 loci. A 9p21 haplotype marked by lead single nucleotide polymorphism rs10757278-G (MAF 43%), an intergenic variant, was replicated and associated with increased CAC quantity (23.4%; 95% confidence interval [CI], 18.6%-28.3%; P=2×10 −24 ). Similarly, rs9349379-G (MAF 34%), an intronic variant within PHACTR1, was associated with increased CAC quantity (20.9%; 95% CI, 16.3%-25.8%; P=5×10 −20 ). Although these associations were robust for those of European ancestry, there was no apparent evidence for association in those of African ancestry (Figures II and III in the Data Supplement). Both loci display locus heterogeneity, or multiple independent associations, for CAC in those of European ancestry (Table 1) . We did not discover noncoding variants at other loci on the exome chip that met our stringent Bonferroni alpha threshold. Previously, rs3809346, an intronic variant of COL4A2, had a suggestive association with CAC, 12 but now in our European ancestry sample size that is twice as large, genome-wide significant association was not observed (P=2×10 −3 ).
Among functional variants, a nonsynonymous APOB (rs5742904-T; MAF 0.2%; NM_000384.2:c.10580G>A; NP_000375.2:p.Arg3527Gln) variant was found to be significantly associated with CAC quantity. Carriers of the rare APOB missense variant had markedly increased CAC (4.1fold; 95% CI, 2.6-to 6.4-fold; P=3×10 −10 ). In our meta-analysis, the Old Order Amish cohort primarily accounted for the strong association, and the variant was extremely rarely observed within other cohorts. Furthermore, the variant was not seen among individuals of African ancestry ( Figure IV in the Data Supplement). We also discovered a distinct rare APOB missense variant (rs1801696-T; MAF 0.6% European ancestry;
NM_000384.2:c.7696G>A; NP_000375.2:p. Glu2566Lys), detected in individuals of European ancestry in most cohorts, that was moderately associated with increased CAC (1.9-fold; 95% CI, 1.6-to 2.1-fold; P=9×10 −6 ). This variant was not observed in individuals of African ancestry.
Additionally, a missense 19q13 variant within the APOE gene (rs7412-T; MAF 7.4% European ancestry, 10.8% African ancestry; NM_000041.2:c.526C>T; NP_000032.1:p.Arg176Cys) was found to be associated with diminished CAC quantity (−22.3%; 95% CI, −27.6% to −16.7%; P=1×10 −12 ; Figure V in the Data Supplement). This association was consistent in those of both European ancestry (−17.3%; 95% CI, −23.7% to −10.3%; P=4×10 −6 ) and African ancestry (−35.2%; 95% CI, −43.6 to −25.7%; P=5×10 −10 ) without significant heterogeneity (P=0.53; Figure 2 ). Additionally, an independent variant (rs769449-A; MAF 11% European ancestry, 2.4% African ancestry) within an intron of APOE also had nominal evidence of association with increased CAC quantity only in individuals of European ancestry (+15.0%; 95% CI, 7.9% to 22.6%; P=2×10 −5 ).
To improve power of discovery for rare protein-coding variants, we conducted gene-based analyses by aggregating such variants within a gene into a single statistical unit to increase the exposure rate. However, collapsing nonsynonymous variants on the exome chip within a gene did not yield genome-wide significant results ( Figure VI in the Data Supplement).
CIMT Association
There was no systematic inflation of CIMT associations with any variant ( Figure VII in the Data Supplement). The top meta-analysis association findings are listed in Table 2 , and a Manhattan plot of all associations is presented in Figure 3 .
We noted that in addition to diminished CAC, the rs7412-T APOE ε2 allele was associated with diminished CIMT (−1.4%; 95% CI, −1.8% to −1.0%; P=4×10 −14 ). There was consistency of association across European and African ancestry cohorts (Figure 4 ; Figure VIII in the Data Supplement). There was no significant heterogeneity among the cohorts for this association (P heterogeneity =0.23).
There were 2 additional independent suggestive associations at 19q13 at noncoding variants. A variant 5 kb upstream of LDLR (rs11668477) was associated with diminished CIMT (P=5×10 7 ) primarily among those of European ancestry. This variant has previously been associated with reduced low-density lipoprotein (LDL) cholesterol. 27 The nearby rs7188-G variant (MAF 33% European ancestry and 7.9% African ancestry) within the 3′ untranslated region region of KANK2 was associated with CIMT in those of European ancestry (P=1x10 −6 ). Additionally, a rare missense variant (rs143873045-A; MAF 0.5% African ancestry; NM_001136191.2:c.1274C>T; NP_001129663.1:p. Ser425Leu) in KANK2 only observed in individuals of African ancestry showed suggestive association with increased CIMT (P=4×10 −4 ). Finally, in gene-based analyses, collapsing nonsynonymous variants within a gene did not yield significant associations ( Figure IX 
APOE ε2's Effect Conditional on LDL Cholesterol
We sought to determine whether LDL cholesterol concentration accounted for the observed ε2 association with CAC. First, when restricting the original analysis only to participants with LDL cholesterol measurements (n=20 527), ε2 remained significantly associated with reduced CAC quantity (−22.3%; 95% CI, −25.1% to −19.3%; P=2×10 −11 ; Table III 
APOE ε2's Effect Conditional on ε3 and ε4
Given the absence of ε4 from the array, we sought to determine whether ε2's apparent effect on reduced CAC quantity was because of a referent that includes a previously described risk allele (ε3+ε4). Five thousand eight hundred seventy-two participants had CAC and the major APOE genotypes assessed by polymerase chain reaction. Each APOE genotype's association with CAC (to the ε3/ε3 referent) was performed by cohort and ethnicity and subsequently meta-analyzed with fixed effects. ε2/ε3 was associated with 10.8% reduced CAC (95% CI, −19.6% to −0.01%; P=0.03) and ε2/ε2 with 27.4% reduced CAC (95% CI, −45.2% to −0.04%; P=0.03; Figure X in the Data Supplement).
Concordance of CHD Variants With Subclinical Atherosclerosis Associations
Of the 57 loci previously associated with CHD mainly in individuals of European or South Asian descent, 40 published variants were on the array and available for analysis. Thirty-two of the 40 variants have the same effect direction for CAC and CHD (P=1.8×10 −4 ), whereas only 23 variants were concordant for CIMT (P=0.43) in European ancestry participants ( . A similar analysis with variants at least nominally associated with CIMT showed that 6 of 11 variants had concordant effect directions for CHD (P=0.56).
Replication of Convergent Subclinical Atherosclerosis Finding With CHD
21 182 individuals of European ancestry, independent of the sample for subclinical atherosclerosis investigations, were genotyped by the Illumina HumanExome BeadChip array, of whom 9472 had CHD. 28 In cross-sectional analyses, meta-analysis of rs7412-T confirmed a significantly lower odds of CHD (odds ratio 0.77; 95% CI, 0.71-0.84; P=1.47×10 −10 ).
Discussion
In our exome-wide association analysis for subclinical atherosclerosis in 2 distinct ethnicities, we find that protein-coding mutations in APOB and APOE are associated with subclinical atherosclerosis. Although the association for APOB was driven by a founder mutation in the Amish, a missense mutation in APOE (ε2) was associated with both reduced CAC and CIMT in individuals of European ancestry and African ancestry, even when adjusting for LDL cholesterol concentration. Furthermore, carriers of the ε2 allele had a reduced risk of CHD. Here, we provide evidence for the first exome-wide association across multiple subclinical atherosclerosis traits and multiple ethnicities for APOE ε2.
Both CAC and CIMT have been proposed as proximal clinical phenotypes of atherosclerosis that may identify individuals at high risk for developing clinical CHD. However, we see that alleles that associate with increased CHD risk also seem to largely result in increased CAC, which is less consistently observed with CIMT. This is concordant with the prior observation that CAC outperforms CIMT in predicting cardiovascular events. 5, 29 Recently, post hoc analyses in statin trials to prevent cardiovascular disease observed that those with a higher burden of CHD-predisposing alleles are more likely to derive clinical benefit from preventive statin therapy. 30 The APOB p.Arg3527Gln (also known as p.Arg3500Gln) has been previously shown to lead to increased concentrations of LDL cholesterol and premature CHD. 31 Our association signal for this variant was nearly exclusively driven by the Old Order Amish, where it is known to be a founder mutation (MAF 12%) predisposing to increased LDL cholesterol concentrations and CAC quantity through disruption of the LDL receptor-binding domain. 32 We also observed a distinct APOB missense mutation, p.Glu2566Lys, with borderline association with increased CAC quantity. Unlike p.Arg3527Gln, p.Glu2566Lys does not occur within the LDL receptor-binding domain but occurs within a conserved amphipathic motif of the β 2 domain predicted to influence the conversion of very low-density lipoprotein to LDL. 33 Furthermore, we demonstrated that APOE p.Arg176Cys (ε2 allele) was associated with reduced CAC and reduced CIMT in both individuals of European and African ancestry. APOE is an essential mediator of the catabolism and clearance of triglyceride-rich and cholesterol-rich lipoproteins. The major alleles, ε2, ε3, and ε4, have been previously linked to cardiovascular disease, from the candidate gene era, and ε2 is the least common allele. 34, 35 Previously, CHD risk predisposition from ε4 was primarily thought to be mediated by LDL cholesterol-raising effects, but observations with ε2 have been mixed. 35 Similarly, ε4, unlike ε2, has been generally linked to ischemic stroke risk. 36 Major reasons for the lack of association of the major APOE alleles with cardiovascular traits in prior genome-wide association studies include the notable absence of rs7412 and rs429358 on populationbased genotyping arrays, as well as poor imputation of these variants. Similarly, rs429358 is not included on the array used for this study. ApoE is a major ligand of LDL receptor and a key mediator of remnant lipoprotein particle clearance. 37, 38 The ε2 allele is believed to result in less efficient LDL receptor binding by altering the positive potential. 39 Using publicly available data, ε2 does not impact expression of nearby genes in Genotype-Tissue Expression project nor does it demonstrate enhancer or promoter chromatin marks in Encyclopedia of DNA Elements HepG2 liver cells supporting ε2's direct impact on ApoE itself. ApoE ε2 can alternatively clear lipoproteins via cell-surface heparan sulfate proteoglycan and LDL receptor-related protein. [40] [41] [42] ApoE ε2 transgenic mice crossbred with apolipoprotein B transgenic mice have lower LDL cholesterol. 42 Furthermore, ApoE ε2 transgenic mice lacking LDL receptor still had lower LDL cholesterol, suggesting that hypocholesterolemia appears independent of ε2's effects on LDL receptor. 35, 43 ApoE ε2 impairs lipoprotein lipase-mediated metabolism of very low-density lipoprotein to LDL potentially through the displacement of apolipoprotein C-II, an activator of lipoprotein lipase. 43 The consequent diminished hepatic cholesterol may subsequently increase LDL receptors for apolipoprotein B-containing lipoproteins like LDL.
Interestingly, despite accounting for LDL cholesterol, we observe that ε2 still is highly associated with reduced CAC quantity. It is likely that a single cross-sectional of lipoproteins, although correlates with, does not fully account for lifelong lipoprotein exposures. ApoE ε2 homozygotes who develop type III hyperlipoproteinemia have a marked increase in remnant lipoprotein particles unlike heterozygotes. Analogously, ApoE ε2-overexpressing mice have increased hepatic very low-density lipoprotein production. 42 Thus, although ApoE ε2 heterozygotes may have an increase in very low-density lipoprotein production and decreased triglyceride catabolism via lipoprotein lipase, the observation of similar triglyceride levels compared with noncarriers suggests preservation of, or enhanced, clearance of remnant lipoprotein particles. We hypothesize that ApoE ε2's association with reduced subclinical atherosclerosis may be because of increased clearance of both atherogenic LDL and remnant lipoprotein particles through LDL receptor-dependent and -independent pathways. Further work is needed to test this hypothesis.
Our study has several strengths. First, we perform a genetic association meta-analysis across the largest set of individuals to date for subclinical atherosclerosis in 2 distinct ancestries. Second, we characterize the association of protein-coding genomic variation, which has not been well studied at the population level, with subclinical atherosclerosis. Third, we explore mechanisms of association through lipoprotein-mediation analyses. Fourth, we provide novel insights with both cross-ethnicity and crossatherosclerosis trait observations. Fifth, we relate the associations of these subclinical atherosclerosis genetic variants on risk for CHD.
Although our study has several strengths, we note some key limitations. First, not all protein-coding variation is catalogued on the exome chip. Because of purifying selection, disruptive protein-coding variation is rare. 44 By potentially not accounting for the totality of disruptive variation not on the array, variance is increased and power is not optimized for gene-based analyses. Whole exome sequencing can better address this limitation because such technologies continue to become more cost-effective for large-scale experiments. Second, our analyses of prior associations at noncoding sites are restricted to sites on the exome chip. We were able to robustly replicate prior noncoding association analyses for CAC at 9p21 and 6p24. 12 A prior meta-analysis for CIMT genome-wide association discovered one genome-wide association, an intergenic common variant (rs11781551-A) 385 kb from ZHX2 at 8q24. 7 No variant with modest linkage disequilibrium with this variant was present on the exome chip, thereby, limiting ability for replication. An intronic variant in PINX1 at 8q23 and intergenic variant 2.3 kb from APOC1 at 19q13 previously had suggestive association, but no suitable proxies to replicate association were available on the exome chip. Third, our analysis still demonstrates a paucity of genome-wide associations for these quantitative atherosclerotic traits and highlights an important challenge to ongoing CAC association analyses.
Genetic determinants of CHD have been characterized among individuals of European ancestry, but the strongest association signals have not replicated in those of African ancestry, which may be because of smaller sample sizes hindering statistical power or different key genetic drivers. But now we demonstrate a cardioprotective genetic mechanism in those of European ancestry and African ancestry through the reduction of subclinical atherosclerosis. We propose potential mechanisms and call for renewed attention to APOE ε2 in the genesis of atherosclerosis underlying clinical cardiovascular disease. Finally, given the strong concordance of subclinical atherosclerosis measures and clinical CHD, our findings support a future study of genotypes, subclinical atherosclerosis, and incident CHD.
Sources of Funding
Dr Natarajan is supported by the John S. LaDue Memorial Fellowship in Cardiology, Harvard Medical School. Dr Kavousi is supported by the NWO VENI grant (VENI, 91616079). Infrastructure for the CHARGE Consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology) is supported in part by the National Heart, Lung, and Blood Institute grant R01HL105756. Funding support for the CHARGE Consortium Exome Chip analyses is provided in part by the National Heart, Lung, and Blood Institute grant R01HL120393. Please refer to the Data Supplement regarding additional sources of funding.
Disclosures
Dr Natarajan reports grant support from Amarin Corporation. Dr Borecki is the Executive Director of Analytic Genetics at Regeneron Pharmaceuticals Inc. Dr Išgum reports research grants from Pie Medical Imaging BV and the Netherlands Organisation for Health Research and Development (ZonMw). Dr Franco is employed by ErasmusAGE, a center for aging research across the life course funded by Nestlé Nutrition (Nestec Ltd.), Metagenics Inc, and AXA. Dr Borecki is employed by Regeneron Pharmaceuticals Inc. Dr Reilly is employed by Merck. Dr Nguyen is employed by Biogen. The other authors report no conflicts.
